Ardelyx, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARDX research report →
Companywww.ardelyx.com
Ardelyx, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia.
- CEO
- Michael G. Raab
- IPO
- 2014
- Employees
- 395
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $1.55B
- P/E
- -26.55
- P/S
- 3.62
- P/B
- 10.37
- EV/EBITDA
- -50.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.93%
- Op Margin
- -8.75%
- Net Margin
- -13.58%
- ROE
- -38.11%
- ROIC
- -9.44%
Growth & Income
- Revenue
- $407.32M · 22.09%
- Net Income
- $-61,599,000 · -57.40%
- EPS
- $-0.26 · -52.94%
- Op Income
- $-40,977,000
- FCF YoY
- 4.03%
Performance & Tape
- 52W High
- $8.40
- 52W Low
- $3.49
- 50D MA
- $6.12
- 200D MA
- $6.11
- Beta
- 0.61
- Avg Volume
- 3.79M
Get TickerSpark's AI analysis on ARDX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | RAAB MICHAEL | other | 20,833 |
| May 15, 26 | RAAB MICHAEL | sell | 41,666 |
| May 15, 26 | RAAB MICHAEL | other | 20,833 |
| Apr 20, 26 | Ettenberg Felecia | other | 0 |
| Apr 20, 26 | Ettenberg Felecia | other | 355,000 |
| Apr 15, 26 | RAAB MICHAEL | other | 20,834 |
| Apr 15, 26 | RAAB MICHAEL | sell | 41,668 |
| Apr 15, 26 | RAAB MICHAEL | other | 20,834 |
| Apr 1, 26 | Dinavahi Rajani | other | 0 |
| Apr 1, 26 | Dinavahi Rajani | other | 301,000 |
Our ARDX Coverage
We haven't published any research on ARDX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARDX Report →